Take­da in­vests $760M+ in­to new plas­ma-de­rived ther­a­py man­u­fac­tur­ing site in Japan

The Japan­ese phar­ma gi­ant Take­da will be mak­ing a sig­nif­i­cant in­vest­ment close to home as it ex­pands its ca­pa­bil­i­ties in plas­ma ther­a­py man­u­fac­tur­ing.

Take­da an­nounced on Thurs­day that it will be con­struct­ing a new man­u­fac­tur­ing fa­cil­i­ty to pro­duce plas­ma-de­rived ther­a­pies or PDTs. Ac­cord­ing to a Take­da re­lease, it plans to in­vest $761.8 mil­lion in­to the project, mark­ing its largest in­vest­ment in­to an ex­pan­sion of man­u­fac­tur­ing ca­pac­i­ty in Japan and will be the largest PDT man­u­fac­tur­ing site in the coun­try.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER